CD274 and cancer: Similarly, in the first-line setting, over 60% of patients with PD-L1-positive G/GEJ cancer who received pembrolizumab monotherapy progressed rapidly, with a median PFS of 2.0 months compared with 6.4 months for patients who received chemotherapy, and no survival benefit despite a proportion of these patients sequenced onto second- or third-line treatment [14].